FY2029 EPS Estimates for Pharvaris Lowered by HC Wainwright

Pharvaris N.V. (NASDAQ:PHVS) – Equities researchers at HC Wainwright reduced their FY2029 EPS estimates for shares of Pharvaris in a research note issued on Tuesday, November 11th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $2.19 per share for the year, down from their prior forecast of $2.22. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.10.

Other research analysts have also recently issued research reports about the company. Bank of America raised Pharvaris from an “underperform” rating to a “neutral” rating and upped their price target for the company from $16.00 to $27.00 in a report on Thursday, October 9th. Zacks Research upgraded Pharvaris from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th. Finally, JMP Securities decreased their price objective on shares of Pharvaris from $55.00 to $52.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 13th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.17.

Pharvaris Trading Up 7.5%

NASDAQ:PHVS traded up $1.69 during mid-day trading on Wednesday, reaching $24.32. 5,749 shares of the stock were exchanged, compared to its average volume of 113,013. The business has a fifty day moving average price of $23.06 and a 200 day moving average price of $20.54. Pharvaris has a 1-year low of $11.51 and a 1-year high of $26.33. The firm has a market capitalization of $1.27 billion, a PE ratio of -7.24 and a beta of -2.78.

Hedge Funds Weigh In On Pharvaris

Hedge funds have recently bought and sold shares of the business. TD Asset Management Inc lifted its position in shares of Pharvaris by 27.4% in the second quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock worth $1,751,000 after buying an additional 21,388 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Pharvaris during the 2nd quarter worth $57,000. Palumbo Wealth Management LLC raised its holdings in Pharvaris by 3.2% in the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock worth $256,000 after acquiring an additional 447 shares during the period. Deutsche Bank AG boosted its holdings in Pharvaris by 55.1% during the first quarter. Deutsche Bank AG now owns 28,174 shares of the company’s stock valued at $442,000 after acquiring an additional 10,006 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after acquiring an additional 15,769 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.